EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New Insights into the Anticancer Effects and Toxicogenomic Safety of Two β-Lapachone Derivatives

José Rivaldo De Lima iD, Alexandre José Da Silva Góes, Elizabeth Fernanda De Oliveira Borba, Meykson Alexandre da Silva, Rodrigo Ribeiro Alves Caiana, Maria do Desterro Rodrigues, Mariza Severina De Lima Silva, Cristiano Aparecido Chagas iD, Blandine Baratte iD, Thomas Robert, Stéphane Bach iD, Isabelle Ourliac-Garnier iD und 2 weitere

Pharmaceuticals · 03.06.2025 · 18 (6) · 837

DOI: 10.3390/ph18060837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 03.06.2025. Verfasst von José Rivaldo De Lima und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Antibióticos, Universidade Federal de Pernambuco, Recife 50670-420, Brazil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: β-Lapachone (β-lap) is an o-naphthoquinone with potent antitumor activity. However, its clinical application is hindered by poor solubility and toxicity. Thiosemicarbazone derivatives of β-lap (BV3 and BV5) have demonstrated enhanced selectivity and anticancer efficacy in leukemia cells. Therefore, this study aimed to evaluate the therapeutic potential of these derivatives in solid tumors. Furthermore, the mechanism of tumor cell death, the involvement of protein kinase inhibition, and the toxicogenetic safety of BV3 and BV5 were investigated.

Methods

The cytotoxic effects of BV3 and BV5 were assessed in cancer cell lines and a non-cancerous cell line. The compounds were most effective against HeLa (human cervical adenocarcinoma) cells. For that reason, this type of cell was chosen to study how the compounds might cause cell death, using flow cytometry. Kinase inhibition assays were conducted in vitro and in silico, followed by genotoxicity assessments to determine toxicogenetic safety.

Results

BV3 and BV5 derivatives significantly inhibited cancer cell proliferation after 72 h, with IC50 values ranging from 2.8 to 36.9 µM. BV3 demonstrated superior selectivity (selectivity index: 15.6) when compared to β-lap (selectivity index: 1.9) in HeLa cells. Morphological changes and flow cytometry analysis revealed features of apoptosis and/or necrosis in HeLa cells treated with the compounds BV3 and BV5. Furthermore, among the kinases tested, BV3 and BV5 were more effective in inhibiting the activity of the protein kinases JAK3 and GSK3β. This result was also confirmed by the in silico studies. Additionally, genotoxicity assays indicated an overall favorable toxicogenetic safety profile; however, BV5 exhibited potential genotoxicity at high concentrations.

Conclusions

The findings underscore the anticancer potential of BV3 and BV5 in solid tumors and highlight their mechanism of action, which involves protein kinases. The findings also show that the drugs are selective and relatively safe.

Schlagwörter

Stichwörter der Autor:innen

DNA damageapoptosiskinasesnecrosisquinonethiosemicarbazone

Autor:innen und Institutionen

  • Departamento de Antibióticos, Universidade Federal de Pernambuco, Recife 50670-420, Brazil.
  • Centro Acadêmico de Vitória, Universidade Federal de Pernambuco, Vitória de Santo Antão 55608-680, Brazil.
  • Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, Sorbonne Université, CNRS, UMR8227, F-29680 Roscoff, France.
  • Plateforme de Criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff, Sorbonne Université, CNRS, FR2424, F-29680 Roscoff, France.
  • Cibles et Médicaments des Infections et de L'immunité, IICiMed, UR 1155, Nantes Université, F-44000 Nantes, France.

ORCID-Profile: José Rivaldo De Lima, Cristiano Aparecido Chagas, Blandine Baratte, Stéphane Bach, Isabelle Ourliac-Garnier, Pascal Marchand

Förderung

  • Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Zitieren

APA

De Lima, J. R., Da Silva Góes, A. J., De Oliveira Borba, E. F., da Silva, M. A., Caiana, R. R. A., Rodrigues, M. D. D., De Lima Silva, M. S., Chagas, C. A., Baratte, B., Robert, T., Bach, S., Ourliac-Garnier, I., Marchand, P., & Da Silva, T. G. (2025). New Insights into the Anticancer Effects and Toxicogenomic Safety of Two β-Lapachone Derivatives. Pharmaceuticals, 18(6), 837. https://doi.org/10.3390/ph18060837

Vancouver

De Lima JR, Da Silva Góes AJ, De Oliveira Borba EF, da Silva MA, Caiana RRA, Rodrigues MDD, et al. New Insights into the Anticancer Effects and Toxicogenomic Safety of Two β-Lapachone Derivatives. Pharmaceuticals. 2025;18(6):837. doi:10.3390/ph18060837

BibTeX
@article{DeLima2025,
  author = {De Lima, José Rivaldo and Da Silva Góes, Alexandre José and De Oliveira Borba, Elizabeth Fernanda and da Silva, Meykson Alexandre and Caiana, Rodrigo Ribeiro Alves and Rodrigues, Maria do Desterro and De Lima Silva, Mariza Severina and Chagas, Cristiano Aparecido and Baratte, Blandine and Robert, Thomas and Bach, Stéphane and Ourliac-Garnier, Isabelle and Marchand, Pascal and Da Silva, Teresinha Gonçalves},
  title = {New Insights into the Anticancer Effects and Toxicogenomic Safety of Two β-Lapachone Derivatives},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {6},
  pages = {837},
  doi = {10.3390/ph18060837}
}
Kostenlos starten →